The results of this first-in-human study of CAN-3110 demonstrate a median overall survival that was substantially longer than the six to nine months typically observed in recurrent high-grade glioma as well as a favorable safety profile.
https://www.businesswire.com/news/home/20210604005138/en/Candel-Therapeutics-Announces-Data-from-Phase-1-Trial-of-CAN-3110-in-Recurrent-High-Grade-Glioma-at-the-2021-American-Society-of-Clinical-Onc…
Candel Therapeutics at the Jefferies Virtual Healthcare Conference 2021
Candel Therapeutics, Inc., a late clinical stage biopharmaceutical company developing novel oncolytic viral immunotherapies, today announced that Paul Peter Tak, M.D. Ph.D., President and Chief Exec…
Carrie Cox joins the Candel team and lead our Board of Directors
We are delighted to have Carrie Cox join the Candel team and lead our Board of Directors. Her strategic insights will be key as we advance our late stage pipeline of agents with the potential to bec…
Prof Paul Peter Tak: Rheumatology, Real Impact and Comfort Zones
In this week’s podcast episode, Professor Paul Peter Tak joins us as we delve into the multifaceted facets of his life, starting from his formative years growing up in the Netherlands. Professo…
The Story of Flagship Pioneering and The Future of Medicines
James is delighted to be joined by the accomplished Dr. Paul-Peter Tak, currently serving as the Venture Partner at Flagship Pioneering and holding the esteemed position of CEO at Kintai Therapeutic…
